Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Mesa on the Unique Characteristics of Momelotinib in Myelofibrosis

January 26th 2022

Ruben A. Mesa, MD, discusses the unique characteristics of momelotinib in myelofibrosis.

Momelotinib Significantly Improves Symptoms, Anemia, and Splenic Size in Myelofibrosis

January 25th 2022

Momelotinib provided a statistically significant benefit in terms of splenic symptoms, anemia, and splenic size in patients with myelofibrosis.

FDA Grants Orphan Drug Designation to Eltanexor for Myelodysplastic Syndromes

January 24th 2022

The FDA has granted an orphan drug designation to eltanexor, an investigational novel SINE compound, as a potential therapeutic option for patients with myelodysplastic syndromes.

What to Know About Polycythemia Vera and Treatment Options

January 24th 2022

Angela Fleischman, MD, PhD, and Stephen Oh, MD, PhD, discuss polycythemia vera (PV) and the possible therapies that can be used to treat patients.

Understanding Essential Thrombocythemia And Treatment Options

January 24th 2022

Stephen Oh, MD, PhD, and Ruben Mesa, MD, explain the fundamentals of essential thrombocythemia (ET) and its treatment options.

Dr. Mesa on Future Research Efforts With JAK Inhibitors in Myelofibrosis

January 21st 2022

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses future research efforts with JAK inhibitors in myelofibrosis.

Dr. Harrison on Unmet Needs in Myelofibrosis

January 19th 2022

Claire Harrison, MD, FRCP, FRCPath, discusses current unmet needs in myelofibrosis.

Dr. Gerds on the Rationale for the Real-World REVEAL Study in Polycythemia Vera

January 17th 2022

Aaron T. Gerds, MD, MS, discusses the rationale for the real-world REVEAL study in polycythemia vera.

Luspatercept Under Exploration in Myeloproliferative Neoplasm–Associated Myelofibrosis

January 17th 2022

The safety and efficacy of luspatercept vs placebo is under exploration in patients with myeloproliferative neoplasm–associated myelofibrosis who are receiving concomitant JAK2 inhibitor therapy and who require red blood cell transfusions, as part of the phase 3 INDEPENDENCE trial.

Dr. Mesa on JAK Inhibitors and Other Promising Novel Agents in Myelofibrosis

January 13th 2022

Ruben A. Mesa, MD, discusses JAK inhibitors and other promising agents in the myelofibrosis therapeutic landscape.

Oral Decitabine Plus Cedazuridine Combo Shows Promise in Lower-Risk MDS

January 12th 2022

James K. McCloskey, MD, discusses the efficacy of oral decitabine plus cedazuridine, the combination’s potential role in lower-risk myelodysplastic syndromes, and what this could mean for the patient population.

Dr. Verstovsek on the Goal of the IMPactMF Trial With Imetelstat in Myelofibrosis

January 11th 2022

Srdan Verstovsek, MD, PhD, discusses the key objective of the phase 3 IMpactMF trial examining imetelstat in patients with myelofibrosis.

CA-4948 Shows Early Activity, Tolerability in Relapsed/Refractory AML and High-Risk MDS

January 7th 2022

CA-4948 monotherapy was found to have preliminary activity with acceptable safety and tolerability in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes, according to updated data from an ongoing phase 1/2 trial.

Dr. Kremyanskaya on the Next Steps of the MANIFEST Trial in Myelofibrosis

January 3rd 2022

Marina Kremyanskaya, MD, PhD, discusses the next steps of the phase 1/2 MANIFEST trial in myelofibrosis.

Ruxolitinib Combos Are Making Strides in Myelofibrosis and MPNs

January 3rd 2022

Marina Kremyanskaya, MD, PhD, discusses potential new combinations for treating patients with myelofibrosis and other MPNs, with a backbone of ruxolitinib.

Novel Agents Shake Up Myelodysplastic Syndrome Treatment Landscape

December 27th 2021

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts shared their insights on the most recent FDA-approved agents for MDS, including luspatercept and decitabine/cedazuridine (Inqovi), both of which were approved in 2020.

An Introduction to Myeloproliferative Neoplasms

December 23rd 2021

Jamile Shammo, MD, FACP, FASCP, provides an overview of the different types of myeloproliferative neoplasms.

Dr. Kremyanskaya on the Design of the MANIFEST Trial in Myelofibrosis

December 21st 2021

Marina Kremyanskaya, MD, PhD, discusses the design of the phase 1/2 MANIFEST trial in myelofibrosis.

Full-Dose Pacritinib Bests Ruxolitinib for Patients With Cytopenic Myelofibrosis

December 14th 2021

Most patients with myelofibrosis with moderate to severe thrombocytopenia treated with pacritinib were able to maintain full dose intensity over time and had numerically higher rates of symptom response vs those who received ruxolitinib.

Serum Ferritin Predicts Treatment Response in Myelofibrosis for Those Assigned to Momelotinib

December 14th 2021

Serum ferritin at baseline was a predictor for week 24 transfusion independence response in patients with myelofibrosis receiving momelotinib according to findings from an analysis of data from the phase 3 SIMPLIFY trials.